Navigation Links
Knowing doctor's financial interests doesn't deter clinical trial participants
Date:4/2/2008

DURHAM, N.C. -- A patient's willingness to participate in a clinical trial may be unaffected by the disclosure of a researcher's financial interests in the study, unless the amount of money a researcher stands to earn depends on the results of the trial, according to a new study by researchers at the Duke Clinical Research Institute (DCRI), Wake Forest University, and the Johns Hopkins Berman Institute of Bioethics.

We found that the patients we surveyed rated most types of financial disclosures less important in influencing their decisions to participate than other factors, like the risks and benefits of the proposed treatment, said Kevin Weinfurt, Ph.D., deputy director of the DCRIs Center for Clinical and Genetic Economics, and lead investigator on the study. We also found that some patients are savvy enough to distinguish between different types of financial relationships, and they have different reactions based on these distinctions.

The researchers published their findings in the April 2, 2008 online edition of the Journal of General Internal Medicine. The study was funded by the National Heart, Lung and Blood Institute.

More than 3,600 diabetes and asthma patients were surveyed for this study, and the researchers asked each to answer questions related to their willingness to participate in a hypothetical clinical trial. Each electronic survey contained one of five financial disclosure statements.

The disclosure statements ranged from the generic -- the doctor running the trial might benefit financially from the study -- to the more specific -- dealing with per capita payments, and ownership of equity on the part of the researcher or the institution, Weinfurt said. We found that none of the disclosures significantly affected subjects willingness to participate with the exception of ownership of equity on the part of the researcher.

This disclosure stated that the study leader could gain or lose money depending on the outcome of the study, Weinfurt said. Nearly 30 percent of respondents presented with this disclosure were unwilling to participate in the trial, as compared to 25 percent of respondents presented with a generic disclosure, and 20 percent of those who were told the investigator received payments from industry to cover the cost of running the study.

Its likely that patients felt ownership of equity could influence the researchers behavior in the trial, which might jeopardize the patients rights and welfare, he said.

In addition to their willingness to participate in the trial, the subjects reactions to the financial disclosures were also assessed as they related to level of surprise, confidence in the quality of the science, and trust of the researcher and the institution.

Interestingly, we found that trust seemed to be the most affected, although it didnt necessarily correlate with their willingness to participate, Weinfurt said. One-third of the respondents said the financial disclosures made them less trusting of the researcher or the institution, but further studies will be needed to really tease out the implications of this.

It is essential that clinical research is a trustworthy endeavor, so we need to think carefully about the implications of these findings, said Jeremy Sugarman, M.D., a professor of bioethics and medicine at the Johns Hopkins Berman Institute of Bioethics and senior author of the study.

The relationships between researchers and industry are becoming more complex, Weinfurt said, leading to greater interest and visibility for this issue as it relates to patients.

The Department of Health and Human Services, among other organizations, has issued a call to the scientific and medical communities to consider whether disclosing financial relationships between investigators and industry during the consent process would help protect the rights and welfare of patients. Our data can help answer this question, Weinfurt said. This study is one of several projects conducted as part of the Conflict of Interest Notification Study (COINS), led by Sugarman.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Veterinary Pet Insurance Data Reveals Well-Intended Pet Owners Unknowingly Poisoning Their Pets
2. Knowing Your Risks Can Stop the Sneak Thief of Sight
3. Knowing Heart Risk Keeps Patients on Cholesterol Drugs
4. Majority of U.S. Doctors Back National Insurance Plan
5. TriWest Recognizes Contributions of TRICARE Docs to Military Community on Doctors Day
6. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
7. Doctors See How Cancer Drug Can Damage Kidneys
8. 3 new honorary doctors at Karolinska Institutet
9. Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS 08
10. Drugs, Doctors and Death: Heath Ledger Becomes Another Victim
11. Doctors should watch for depression in arthritis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: